Harnessing the Power of the Mitochondria to Treat Human Diseases

Mitochon Pharmaceuticals is a biotech company, formed in 2014, that focuses on developing drugs that target the mitochondria for a host of serious diseases with significant unmet medical needs. Our development programs are primarily focused on neurodegenerative & neuromuscular diseases including: Huntington’s Disease, Multiple Sclerosis/Optic Neuritis, Wolfram Syndrome, Epilepsy, Traumatic Brain Injury (TBI), Duchenne Muscular Dystrophy (DMD), Alzheimer’s Disease, and Parkinson Disease. On-going research has linked these diseases to various malfunctions of the mitochondria. By correcting them, Mitochon aims at opening the way for a broad range of disease modifying therapies. Mitochon is led by a team of industry executives with over 100-years of combined experience and a passion to bring forward breakthrough drug therapies for a host of insidious diseases.

No Widgets

The mitochondria are the “powerhouse” of the cells, that use the food we eat to generate ATP (adenosine triphosphate), the universal store of energy. Once ATP is produced, it is then used throughout the body to power a host of cellular functions. These unique organelles can sometimes malfunction causing severe diseases that we are targeting.